Skip to content

Psychiatry Research

ISSN 1872-7123, 0165-1781

164 papers in the library · 1,451 citations · publishing 1983-2026

Papers

Sort Most recent Most cited

Dissociative episodes and concurrent heart rate in patients with PTSD - An ecological momentary assessment.

Psychiatry Research 2025 Sarah Beutler-Traktovenko, Marcel Franz, Judith Daniels et al.

Dissociative symptoms are a frequent complication in posttraumatic stress disorders affecting about a third of all PTSD patients. While theoretical models predict a physiological hypoarousal during posttraumatic dissociations, empirical evidence is lacking. We addressed this by studying spontaneously occurring dissociative symptoms and related heart rate changes in an ecological momentary...

Change starts with the body: Interoceptive appreciation mediates the effect of mindfulness training on behavior change - an effect moderated by depression severity.

Psychiatry Research December 1, 2024 Zev Schuman-Olivier, Richa Gawande, Timothy B. Creedon et al. 10 citations

Mindfulness catalyzes health behavior change. Yet, interoception is dysregulated in depression, potentially impairing behavioral activation. We examined the mediating role of interoceptive appreciation, as measured by how much one trusts and listens to internal bodily signals, on behavior change. Primary care patients with depression, anxiety, or stress disorders related to chronic illness were...

Effects of mindfulness-based interventions (MBIs) on psychotic symptoms and psychological outcomes in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis.

Psychiatry Research December 1, 2024 Chuntana Reangsing, Sathit Wongsuraprakit, Sasinun Punsuwun et al. 5 citations

Mindfulness refers to the practice of consciously attending to the present moment without judgement. Although mindfulness-based intervention have been extensively researched. Less is known about the effect of this intervention on psychotic symptoms in patients with schizophrenia spectrum disorders. Thus, we synthesized the effects of mindfulness-based interventions (MBIs) on psychotic symptoms,...

DOI: 10.1016/j.psychres.2024.116272 (opens in new tab) Full text (opens in new tab) Meta-analysis Mindfulness-based interventions Schizophrenia

Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial.

Psychiatry Research December 1, 2024 Shampa Maji, Archana Mishra, Debadatta Mohapatra et al. 5 citations

Therapeutic latency, lack of response, and adverse drug reactions are major challenges in current treatment approaches for major depressive disorder (MDD). Following the success of ketamine, more clinical research on NMDA antagonists is needed for a safe and long-term therapy in MDD. Hence, this study was conducted to evaluate the efficacy and safety of adjunct dextromethorphan to SSRIs in MDD....

Investigating change in the ability to decentre and depressive symptomatology over the course of a six-month mindfulness-based intervention in patients with persistent depression.

Psychiatry Research November 1, 2024 Jonathan Hamilton, Thorsten Barnhofer 2 citations

Mindfulness-based interventions (MBIs) for depression use regular mindfulness practice as a means of helping patients build skills that allow them to respond more adaptively to negative mood. Although effects of practice are assumed to accumulate over time, little is known about the trajectories of change in skills and symptoms beyond the duration of standard eight-week interventions....

Hallucinations across sensory domains in people with post-traumatic stress disorder and psychosis

Psychiatry Research October 11, 2024 Robert Dudley, Sarah White, Rebecca Miskin et al. 4 citations

Auditory hallucinations are common in people with histories of adversity, possibly indicating a causal relationship. However, hallucinations occur in multiple sensory modalities and the relationship between trauma and hallucinations in other sensory domains is less explored. We examined the occurrence of hallucinatory experiences in different sensory modalities in people with psychosis who also...

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.

Psychiatry Research October 1, 2024 Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran et al. 17 citations

Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi-site observational study aiming to assess the real-world effectiveness and tolerability of these novel therapies in the management of MDD-TRD. 53 patients were referred to receive IV ketamine (n = 26, 69.23 % female,...

Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.

Psychiatry Research October 1, 2024 Je-Yeon Yun, Yong‐Ku Kim 11 citations

Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants with an adequate dosage and treatment duration. The NMDA receptor antagonist ketamine rapidly reduces depressive symptoms in TRD. We examined neural correlates of treatment response to ketamine in TRD through a systematic review of brain magnetic...

Efficacy of yoga for posttraumatic stress disorder: A systematic review and meta-analysis of randomized controlled trials.

Psychiatry Research October 1, 2024 Seyed Aria Nejadghaderi, Seyed Ehsan Mousavi, Asra Fazlollahi et al. 11 citations

Yoga is an increasingly popular complementary intervention to reduce posttraumatic stress disorder (PTSD) symptoms and related comorbidities, but its safety and treatment efficacy are not firmly established. We conducted a systematic review and meta-analysis of existing randomized control trials (RCTs) of yoga interventions for PTSD and related secondary outcomes (e.g., depression). Initial...

Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs.

Psychiatry Research September 1, 2024 Qinghua Guo, Libo Guo, Yong Wang et al. 19 citations

Treatment-Resistant Depression (TRD) challenges psychiatric treatment, with existing guidelines covering only a subset of augmentation strategies. A network meta-analysis following PRISMA guidelines examined the efficacy and safety of TRD treatments, analyzing 72 randomized controlled trials from eight databases, assessing response and remission rates, tolerability, and safety through the...

DOI: 10.1016/j.psychres.2024.116018 (opens in new tab) Full text (opens in new tab) Enhanced innovative therapies Network meta-analysis Treatment-resistant depression trd Refractory depression +3

Ketamine versus electroconvulsive therapy for major depressive episode: An updated systematic review and non-inferiority meta-analysis.

Psychiatry Research September 1, 2024 Arthur Bezerra Cavalcanti Petrucci, João Vitor Andrade Fernandes, Isabelle Albuquerque Reis et al. 18 citations

We conducted a systematic review and meta-analysis to investigate the comparative effectiveness of ketamine versus electroconvulsive therapy (ECT) for the treatment of major depressive episodes (MDEs). PubMed, EMBASE and Cochrane Library databases were systematically searched for randomized controlled trials (RCTs) comparing ketamine and ECT for MDE. The primary outcome was response rate, for...

The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials.

Psychiatry Research September 1, 2024 Jianhua Yang, Ni Wang, Wulin Luo et al. 14 citations

3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is one of the most widely used illicit substances worldwide. MDMA-assisted psychotherapy has become a novel treatment for posttraumatic stress disorder (PTSD), and many randomized controlled trials (RCTs) have been performed over the past decade. Therefore, this study aimed to systematically review and demonstrate the efficacy...

Joint-trajectories of clinical severity, social functioning and cannabis use in first-episode psychosis: A 5-year longitudinal study in 2 urban early intervention services.

Psychiatry Research September 1, 2024 Giuseppe D'Andrea, Clairélaine Ouellet-Plamondon, Marie Villeneuve et al.

Cannabis use is associated with increased psychosis incidence alongside worse outcomes. The role of cannabis may be complex, vary across patients and over time. Yet, few have examined the longer-term trajectories of cannabis use, symptoms and functioning and their inter-relationships. We conducted a 5-year longitudinal study to estimate joint-trajectories of clinical severity, social...

Efficacy of addition of the anti-inflammatory, IV glutathione to standard ketamine IV therapy in major depressive disorder.

Psychiatry Research July 1, 2024 Ladan Eshkevari, Michelle Sales, Christina Collins et al. 3 citations

Ketamine, a N-methyl-D-aspartate (NMDA) antagonist, is used for treatment-resistant depression (TRD). Recent studies have shown that there are increased levels of pro-inflammatory cytokines in individuals with major depressive disorder (MDD) and those with higher levels of oxidative stress markers have a decreased or null response to conventional antidepressants. Glutathione (GSH) as an...

Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study.

Psychiatry Research July 1, 2024 Ana Paula Anzolin, Daniel Prates Baldez, Bruno Braga Montezano et al. 2 citations

This investigation explores the efficacy of subcutaneous ketamine for mitigating depressive symptoms and suicidal ideation, addressing a crucial need for rapid-onset treatments in severe depression cases. It introduces an innovative approach to administering an NMDA receptor antagonist, significantly advancing psychopharmacological methods for treating suicidal behaviors as distinct entities,...

DOI: 10.1016/j.psychres.2024.115915 (opens in new tab) Full text (opens in new tab) C-ssrs Suicidal ideation Mental health treatment Depression therapy +3

Mechanisms of therapeutic change after psychedelic treatment in OCD.

Psychiatry Research June 1, 2024 Gayle Maloney, Terence H. W. Ching, Stephen A. Kichuk et al. 3 citations

Novel treatments are required for the 30-50% of individuals with obsessive-compulsive disorder (OCD) who remain resistant to first-line pharmacological and psychotherapeutic treatments. Recent pilot data suggest benefit from psilocybin-assisted psychotherapy (PAP) and from imagery rescripting (ImRs). We explore psychological mechanisms of change underpinning both interventions that appear to...

DOI: 10.1016/j.psychres.2024.115907 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Imagery rescripting imrs Obsessive-Compulsive Disorder OCD Psilocybin-assisted psychotherapy pap +2

Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.

Psychiatry Research May 1, 2024 Yuan Yao, Dan Guo, Tang-Sheng Lu et al. 126 citations

We aim to systematically review and meta-analyze the effectiveness and safety of psychedelics [psilocybin, ayahuasca (active component DMT), LSD and MDMA] in treating symptoms of various mental disorders. Web of Science, Embase, EBSCO, and PubMed were searched up to February 2024 and 126 articles were finally included. Results showed that psilocybin has the largest number of articles on...

DOI: 10.1016/j.psychres.2024.115886 (opens in new tab) Full text (opens in new tab) Mental disorders Meta-analysis Safety Psychedelics hallucinogens +5

Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review.

Psychiatry Research May 1, 2024 Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al. 48 citations

Psychotherapies assisted by psychedelic substances have shown promising results in the treatment of psychiatric disorders. The aim of this systematic review and meta-analysis was to evaluate safety data in human subjects. We carried out a search on MEDLINE, Embase and PsycINFO databases between 2000 and 2022. Standardized mean differences between different dose ranges and between acute and...

Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.

Psychiatry Research May 1, 2024 Balwinder Singh, Sagar V Parikh, Jennifer L. Vande Voort et al. 18 citations

This nonrandomized, multicenter, open-label clinical trial explored the impact of intravenous (IV) ketamine on cognitive function in adults (n = 74) with treatment-resistant depression (TRD). Patients received three IV ketamine infusions during the acute phase and, if remitted, four additional infusions in the continuation phase (Mayo site). Cognitive assessments using the Repeatable Battery...

DOI: 10.1016/j.psychres.2024.115829 (opens in new tab) Full text (opens in new tab) Neurocognition Open-label study Rbans Ketamine infusion +4

IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital.

Psychiatry Research May 1, 2024 Gilmar Gutierrez, Melody J Y Kang, Gustavo Vazquez 12 citations

Individuals with major depressive disorder and treatment resistant depression (MDD-TRD) have limited and sometimes poorly tolerated therapeutic options. Low dose ketamine has presented promising and potent antidepressant effects in this population. To support the existent literature, we conducted a longitudinal study examining five years of real-world clinical data on the use of IV low-dose...

Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans.

Psychiatry Research May 1, 2024 Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra et al. 12 citations

Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking. Herein, we aim to inform prediction models of non-response to ketamine/esketamine in adults with TRD. This is a retrospective analysis of PHQ-9 item response data from 120 patients with TRD who received repeated doses of...

Effect of intraoperative and/or postoperative esketamine administration on preventing postpartum depression: A systematic review and meta-analysis.

Psychiatry Research May 1, 2024 Jinping Wang, Hui Liu, Xinchuan Wei 9 citations

This systematic review and meta-analysis aimed to evaluate the impact of intraoperative and/or postoperative esketamine application on the prevention of postpartum depression (PPD). PubMed, Embase, and Web of Science were thoroughly searched for eligible randomized controlled trials (RCTs) regarding the application of esketamine for postnatal depression prevention. Nine RCTs including 1277...

DOI: 10.1016/j.psychres.2024.115890 (opens in new tab) Full text (opens in new tab) Ketamine Postnatal depression Maternal health Mental health treatment +3

A randomized controlled trial of mindfulness-based cognitive therapy for major depressive disorder in undergraduate students: Dose- response effect, inflammatory markers and BDNF.

Psychiatry Research 2024 Wei Liu, Jing Yuan, Yun Wu et al. 19 citations

To examine the dose-response effect of mindfulness-based cognitive therapy (MBCT) for college students with major depressive disorder (MDD), a randomized control trial with MBCT and a wait-list (WL) group was performed. All participants were invited to self-administer a set of questionnaires at baseline, mid-intervention (4th week), and post-intervention (8th week) by the 9-item Patient Health...

DOI: 10.1016/j.psychres.2023.115671 (opens in new tab) Full text (opens in new tab) Major depressive disorder Mindfulness-based cognitive therapy Randomized control trial The dose-response effect

Using an Electronic Mindfulness-based Intervention (eMBI) to improve maternal mental health during pregnancy: Results from a randomized controlled trial.

Psychiatry Research December 1, 2023 Kathrin Hassdenteufel, Mitho Müller, Harald Abele et al. 32 citations

Prevalence rates of peripartum depression and anxiety are high and correlate with adverse maternal and neonatal outcomes. Mindfulness-based interventions (MBI) have been shown to reduce mental distress during pregnancy. A multicenter, randomized controlled study was conducted after screening for depressive symptoms. The intervention group (IG) was given access to an 8-week supervised eMBI...

Mindfulness, psychological flexibility and their relationship with psychopathology in persons with schizophrenia-spectrum-disorders and healthy controls - A multicenter cross-sectional study.

Psychiatry Research December 1, 2023 Kerem Böge, David J Hallford, Matthias Pillny 9 citations

The precise nature of the relationship between mindfulness, psychological flexibility (PF) and psychopathology in schizophrenia spectrum disorders (SSD) remains largely unclear and warrants further investigation. We recruited 43 persons with SSD and 43 controls. Our findings revealed that SSD showed lower mindfulness and PF than controls. Mindfulness was associated with higher PS, anticipatory...